Chris Dealwis

Find an error

Name: Dealwis, Chris
Organization: Case Western Reserve University , USA
Department:
Title: (PhD)
Co-reporter:Qun Wan;Andrey Y. Kovalevsky;Mark A. Wilson;Brad C. Bennett;Paul Langan
Acta Crystallographica Section F 2014 Volume 70( Issue 6) pp:814-818
Publication Date(Web):
DOI:10.1107/S2053230X1400942X

A crystal of Escherichia coli dihydrofolate reductase (ecDHFR) complexed with folate and NADP+ of 4 × 1.3 × 0.7 mm (3.6 mm3) in size was obtained by sequential application of microseeding and macroseeding. A neutron diffraction data set was collected to 2.0 Å resolution using the IMAGINE diffractometer at the High Flux Isotope Reactor within Oak Ridge National Laboratory. A 1.6 Å resolution X-ray data set was also collected from a smaller crystal at room temperature. The neutron and X-ray data were used together for joint refinement of the ecDHFR–folate–NADP+ ternary-complex structure in order to examine the protonation state, protein dynamics and solvent structure of the complex, furthering understanding of the catalytic mechanism.

Co-reporter:Andrey Kovalevsky;Qun Wan;Brad C. Bennett;Paul Langan;Mark A. Wilson;Elizabeth E. Howell
PNAS 2014 Volume 111 (Issue 51 ) pp:18225-18230
Publication Date(Web):2014-12-23
DOI:10.1073/pnas.1415856111
Dihydrofolate reductase (DHFR) catalyzes the NADPH-dependent reduction of dihydrofolate (DHF) to tetrahydrofolate (THF). An important step in the mechanism involves proton donation to the N5 atom of DHF. The inability to determine the protonation states of active site residues and substrate has led to a lack of consensus regarding the catalytic mechanism involved. To resolve this ambiguity, we conducted neutron and ultrahigh-resolution X-ray crystallographic studies of the pseudo-Michaelis ternary complex of Escherichia coli DHFR with folate and NADP+. The neutron data were collected to 2.0-Å resolution using a 3.6-mm3 crystal with the quasi-Laue technique. The structure reveals that the N3 atom of folate is protonated, whereas Asp27 is negatively charged. Previous mechanisms have proposed a keto-to-enol tautomerization of the substrate to facilitate protonation of the N5 atom. The structure supports the existence of the keto tautomer owing to protonation of the N3 atom, suggesting that tautomerization is unnecessary for catalysis. In the 1.05-Å resolution X-ray structure of the ternary complex, conformational disorder of the Met20 side chain is coupled to electron density for a partially occupied water within hydrogen-bonding distance of the N5 atom of folate; this suggests direct protonation of substrate by solvent. We propose a catalytic mechanism for DHFR that involves stabilization of the keto tautomer of the substrate, elevation of the pKa value of the N5 atom of DHF by Asp27, and protonation of N5 by water that gains access to the active site through fluctuation of the Met20 side chain even though the Met20 loop is closed.
Co-reporter:Dianqing Sun Dr.;Hai Xu Dr.;SanathR. Wijerathna Dr.;RichardE. Lee Dr.
ChemMedChem 2009 Volume 4( Issue 10) pp:1649-1656
Publication Date(Web):
DOI:10.1002/cmdc.200900236

Abstract

Analysis of the recently solved X-ray crystal structures of Saccharomyces cerevisiae ribonucleotide reductase I (ScRnr1) in complex with effectors and substrates led to the discovery of a conserved water molecule located at the active site that interacted with the 2′-hydroxy group of the nucleoside ribose. In this study 2′-(2-hydroxyethyl)-2′-deoxyadenosine 1 and the 5′-diphosphate derivative 2 were designed and synthesized to see if the conserved water molecule could be displaced by a hydroxymethylene group, to generate novel RNR inhibitors as potential antitumor agents. Herein we report the synthesis of analogues 1 and 2, and the co-crystal structure of adenosine diphosphate analogue 2 bound to ScRnr1, which shows the conserved water molecule is displaced as hypothesized.

Thymidine 5'-(tetrahydrogen triphosphate), 2-thio-
2-AMINO-2'-DEOXYADENOSINE 5'-TRIPHOSPHATE
9H-Purin-2-amine,9-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-b-D-erythro-pentofuranosyl]-
[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(6-oxo-3H-purin-9-yl)oxolan-2-yl]methoxy]phosphoryl]oxy-phosphoryl]oxyphosphonic acid
7H-Pyrrolo[2,3-d]pyrimidin-4-amine,7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-b-D-ribofuranosyl]-
Uridine 5'-(tetrahydrogen triphosphate), 2'-deoxy-5-fluoro-
2'-Deoxyuridine-5'-triphosphoric acid = dUTP
GUANOSINE
2-(butylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridin-3-amine
1H-Indole, 1-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-5-nitro-